Fungal Infections

Vulnerable immunocompromised individuals are at risk of opportunistic infections by invasive molds, and available antifungal treatments for these invasive infections are currently restricted. Therefore, a combination of therapies has been proposed as a potential strategy to enhance the effectiveness of treatment outcomes. Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals Cleveland Medical Centre, […]

Antifungal resistance is an increasing concern in the treatment of fungal infections, especially when there are already limited options in the treatment paradigm. It was a pleasure to talk with Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Center for Medical Mycology, Cleveland, OH, USA) around the impact of biofilms on antifungal therapy, […]

Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Centre for Medical Mycology, Cleveland, OH, USA) joins us to discuss ECCMID 2023 highlights in fungal infections, antifungal therapies, diagnostic approaches, and specific case reports that help advise clinicians in clinical practice. Interviews in this series: Ibrexafungerp against Mucor strains using time-kill and scanning electron […]

Intravenous amphotericin B is a mainstay of treatment in cryptococcal meningitis, in this phase 2 study the efficacy and safety of amphotericin B, a novel, orally absorbed, less-toxic formulation is investigated. It was a pleasure to talk with Prof. David Boulware (University of Minnesota, Minneapolis, USA) to learn more around the prevalence, clinical presentations and […]

The phase 3 ReSTORE trial (NCT03667690) was a randomized, double-blind, non-inferiority study comparing the efficacy and safety of rezafungin with caspofungin in the treatment of candidemia and/or invasive candidiasis. touchINFECTIOUS DISEASES had the opportunity to speak with Dr. Alex Soriano (University of Barcelona, Barcelona, Spain) to discuss the unmet needs and mortality in candidemia and […]

Fungal infections pose a high risk in patients with a weakened immune system, despite the development of new antifungal therapeutics, antifungal resistance is an increasing concern when trying to treat patients. We were delighted to catch up with Prof. David Denning (The University of Manchester, Manchester, United Kingdom) around his highlights from ECCMID, including new […]

Chronic pulmonary aspergillosis (CPA) is a complicated respiratory disease associated with high morbidity and mortality rates. This overlooked disease often comes with delayed diagnosis and treatment, demonstrating a need for increased awareness and education in this area. We met with Prof. David Denning (The University of Manchester, Manchester, United Kingdom) to discuss the current state […]

ReSTORE (NCT03667690) was a phase 3, randomised, double-blind, non-inferiority trial comparing the efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis. We were delighted to talk with Prof. George Thompson (University of California, Davis, School of Medicine, Sacramento, CA, USA) around the ReSTORE analysis investigating all-cause and attributable mortality with rezafungin. Access […]

Rezafungin, an echinocandin antifungal, was recently investigated in the phase 2 STRIVE (NCT02734862) and phase 3 ReSTORE (NCT03667690) trials in candidaemia/invasive candidiasis. In this interview with Prof. George Thompson (University of California, Davis, School of Medicine, Sacramento, CA, USA) we talk about the pooled analysis of STRIVE and ReSTORE, looking at mycological response with rezafungin […]